ClinicalTrials.gg
CompletedNCT05228470Updated Sep 29, 2026Results posted

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

A Phase 2 interventional study of Elranatamab in Elranatamab, Myeloma and Multiple Myeloma, sponsored by Pfizer. Completed at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Primary conditionMultiple MyelomaRegistry: Neoplasms, Plasma CellReclassifiedWhy we changed it
Registry
Neoplasms, Plasma Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. The study's listed conditions name Multiple Myeloma, a narrower term within Neoplasms, Plasma Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Updated Sep 29, 2026Study documents postedPosted results revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.

Enrollment
24th of 31
39 · median 75
Started
2021
with 5 others
Phase 2
18 of 31
12 open now
Registered
7th of 31
by date
Lead sponsor
13 of 31
Pfizer

Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 24th largest by enrollment, is one of 6 that started in 2021, is one of 18 in phase 2, and was the 7th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About elranatamab

elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing elranatamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to understand the study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma. Multiple myeloma is a form of cancer in the bone that forces healthy blood cells to go out. Sometimes, multiple myeloma does not respond to current therapy or quickly progresses, and this is called refractory multiple myeloma.

Elranatamab is a study medicine that target multiple myeloma and activates the human body to fight against this disease. We are seeking Chinese participants to take part in this study. The study will be 2 parts, called part 1b and part 2. In part 1b, participants will receive Elranatamab at 2 steps priming and full dose as a sc (subcutaneous injection) therapy. We will monitor participants' safety and reactions to the study medicine. This will help us understand the dosage of Elranatamab to be used safely.

In part 2 of the study, participants will receive Elranatamab and their multiple myeloma growth will be monitored. This will help us understand if Elranatamab, when used alone, may be a therapy for refractory multiple myeloma. Participants in this part of the study are expected to take part for about 2 years.

03

Conditions studied

  • Elranatamab
  • Myeloma
  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • PF-06863135
  • BCMA
  • Bispecific
  • Bispecific Antibody
  • BCMA-CD3 Bispecific
  • MagnetisMM-8

Keywords

  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Neoplasms by Histologic Type
  • Neoplasms
  • Hemostatic Disorders
  • Vascular Diseases
  • Cardiovascular Diseases
  • Paraproteinemias
  • Blood Protein Disorders
  • Hematologic Diseases
  • Hemorrhagic Disorders
  • Lymphoproliferative Disorders
  • Immunoproliferative Disorders
  • Immune System Diseases
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 39 is close to the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms, Plasma Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)
  • , as defined by at least 1 of the following:
  • Serum M-protein ≥0.5 g/dL
  • Urinary M-protein excretion ≥200 mg/24 hours
  • Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
  • to at least one IMiD
  • Refractory to at least one PI
  • Refractory to at least one anti-CD38 antibody
  • Relapsed/refractory to last anti-myeloma regimen
  • performance status ≤2
  • Adequate BM function characterized by the following:

    1. ≥1.0 × 10\^9/L
    2. ≥ 25 × 10\^9/L
    3. ≥8 g/dL
  • Resolved acute effects of any prior therapy to baseline severity or Grade ≤1
  • Not pregnant and willing to use

Exclusion criteria

Exclusion Criteria:

  • Smoldering multiple myeloma
  • Active Plasma cell leukemia
  • Amyloidosis
  • POEMS syndrome
  • Stem cell transplant or active within 12 weeks prior to enrollment.
  • Previous treatment with an anti-BCMA directed therapy
  • Impaired cardiovascular function or cardiovascular diseases
  • Ongoing Grade ≥2 peripheral sensory or motor neuropathy. History of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.
  • Active , , SARS-CoV2, , or any active, uncontrolled bacterial, fungal, or viral infection
  • Any other active within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • Previous administration with an drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Elranatamab

    BCMA-CD3 bispecific antibody

    Drug: Elranatamab

Interventions

  • BCMA-CD3 bispecific antibody

    Also known as: PF-06863135

07

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)

    Grade(G)4 neutropenia \>5 day; febrile neutropenia (absolute neutrophil count \[ANC\] \<1000/millimeter cube (mm\^3) with single temperature \>38.3 degree Celsius (deg C) or sustained temp\>=38 deg C for \>1 hour(H); G\>=3 neutropenia with infection; G4 thrombocytopenia (unless baseline count \>=25,000/mm\^3 and \<50,000/mm\^3, in which case G4 thrombocytopenia to be accompanied by \>=G2 bleeding); Platelet count \<10,000/mm\^3; G3 thrombocytopenia with \>=G2 bleeding; G\>=4 AE; G3 cytokine release syndrome(CRS) except CRS not maximally treated/improved to \<=G1 within 48H; G3 AE except AE attributed to CRS, G3 nausea,vomiting,diarrhea improved to G\<=2 within 72H after medical management, G3 fatigue \<1 week, G3 AE recovered to baseline/G1 within 5 day; confirmed drug-induced liver injury; G3-4 laboratory (lab) abnormality except G3-4 lab abnormality improved to G\<=2 within 72H after medical management \& without sequelae;G3 injection site reaction; G2/other clinically important AE may be considered DLT.

    Time frame: Cycle 1 (28 days)

  2. Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria

    ORR: Percentage of participants with best overall response (BOR) of confirmed stringent complete response (sCR), CR, very good partial response (VGPR) or PR per IMWG criteria. sCR: CR and normal serum free light chain (sFLC) ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum \& urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein \& reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum \& urine M-protein were unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% \& \>=50% reduction in soft tissue plasmacytomas' size.

    Time frame: From date of first dose until confirmed disease progression (PD), death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)

Secondary outcomes

  1. Duration of Response (DOR) as Per IMWG Criteria by BICR

    DOR: Time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell percentage irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion, \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

    Time frame: From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)

  2. DOR as Per IMWG Criteria by Investigator Assessment

    DOR: Time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell percentage irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

    Time frame: From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)

  3. Complete Response Rate (CRR) as Per IMWG Criteria by BICR

    CRR: Percentage of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/bone marrow aspiration (BMB/BMA) by immunohistochemistry (IH), immunofluorescence (IF), or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.

    Time frame: From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)

  4. CRR as Per IMWG Criteria by Investigator Assessment

    CRR: Percentage of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.

    Time frame: From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)

  5. ORR as Per IMWG Criteria by Investigator Assessment

    ORR: Percentage of participants with best overall response of confirmed sCR, CR, VGPR or PR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein and urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein were unmeasurable, VGPR and PR: \>=90% and \>=50% decrease in difference respectively between involved and uninvolved sFLC levels and if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.

    Time frame: From date of first dose until confirmed PD, death due to any cause, or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)

  6. Duration of Complete Response (DOCR) as Per IMWG Criteria by BICR

    DOCR: Time from first documentation of sCR/CR subsequently confirmed, until first documentation of confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

    Time frame: From the first documentation of sCR/CR, until confirmed PD, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)

  7. DOCR as Per IMWG Criteria by Investigator Assessment

    DOCR: Time from first documentation of sCR/CR subsequently confirmed, until first documentation of confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

    Time frame: From the first documentation of sCR/CR, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)

  8. Progression Free Survival (PFS) as Per IMWG Criteria by BICR

    PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

    Time frame: From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)

  9. PFS as Per IMWG Criteria by Investigator Assessment

    PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

    Time frame: From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)

  10. Overall Survival (OS)

    OS was defined as time from date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive

    Time frame: From the date of first dose until death due to any cause or censoring date (up to 38.8 months of follow-up)

  11. Time-to-Response (TTR) as Per IMWG Criteria by BICR

    TTR, for participants with objective response (OR) per IMWG criteria: time from date of first dose to first documentation of OR that was subsequently confirmed. OR: BOR of confirmed sCR, CR, VGPR or PR. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measured sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/ \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.

    Time frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)

  12. TTR as Per IMWG Criteria by Investigator Assessment

    TTR, for participants with OR per IMWG criteria: time from date of first dose to first documentation of OR that was subsequently confirmed. OR: BOR of confirmed sCR, CR, VGPR or PR. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measured sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/ \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.

    Time frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)

  13. Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria by BICR

    MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/ bone marrow aspirate (BMB/BMA) by immunohistochemistry, immunofluorescence, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. MRD negativity rate at threshold of 10\^-5 is reported in this outcome measure.

    Time frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)

  14. MRD Negativity Rate Per IMWG Sequencing Criteria by Investigator Assessment

    MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/ bone marrow aspirate (BMB/BMA) by immunohistochemistry, immunofluorescence, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. MRD negativity rate at threshold of 10\^-5 is reported in this outcome measure.

    Time frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)

  15. Number of Participants With Treatment Emergent Adverse Events (TEAE), Serious TEAEs, Treatment Related TEAEs, Serious Treatment Related TEAEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    AE: any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to study intervention. Serious adverse event (SAE): any untoward medical occurrence that, at any dose resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. An AE was considered treatment-emergent if it occurred from the first dose of the study intervention until 90 days after the last dose or the day before starting a new anticancer therapy, whichever occurred first. AEs included both SAEs and all other AEs. AEs were graded using CTCAE version 5.0, where Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening; Grade 5: death. Relatedness to study intervention was judged by investigator.

    Time frame: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)

  16. Number of Participants With Cytokine Release Syndrome (CRS) of Any Grade According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria

    ASTCT CRS Grading: Grade 1: temperature \>=38 degree Celsius (deg C) without hypotension or hypoxia; Grade 2: temperature \>=38 deg C with hypotension not requiring vasopressors, and/or hypoxia requiring low-flow nasal cannula, facemask or blow-by; Grade 3: temperature \>=38 deg C with hypotension requiring a vasopressor with or without vasopressin and/or hypoxia requiring high-flow nasal cannula, high-flow facemask, nonrebreather mask, or Venturi mask; Grade 4: temperature \>=38 deg C with hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive pressure (e.g., continuous positive airway pressure \[CPAP\], bilevel positive airway pressure \[BiPAP\], intubation and mechanical ventilation); Grade 5: death. Number of participants with CRS of any grade is reported in this outcome measure.

    Time frame: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)

  17. Number of Participants With Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) of Any Grade According to ASTCT Criteria

    ICANS Grade 1: immune effector cell encephalopathy (ICE) score 7-9, participant (P) awakens spontaneously; Grade 2: ICE score 3-6, P awakens to voice; Grade 3: ICE score 0-2, P awakens only to tactile stimulus, any clinical seizure focal or generalized that resolved rapidly/nonconvulsive seizures on electroencephalography that resolved with intervention or focal/local edema on neuroimaging; Grade 4: ICE score 0 (P unarousable and unable to perform ICE), P unarousable/required vigorous/repetitive tactile stimuli to arouse, life-threatening prolonged seizure (\>5 minutes), repetitive clinical/electrical seizures without return to baseline in between, deep focal motor weakness, diffuse cerebral edema on neuroimaging; decerebrate/decorticate posturing; cranial nerve VI palsy; papilledema, Cushing's triad; Grade 5: death. ICE: measures alterations in speech, orientation, handwriting, attention and receptive aphasia. Number of participants with ICANS of any grade reported.

    Time frame: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)

  18. Maximum Serum Concentration (Cmax) of Free Elranatamab

    Time frame: Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)

  19. Time To Maximum Serum Concentration (Tmax) of Free Elranatamab

    Time frame: Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)

  20. Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of Free Elranatamab

    Time frame: Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)

  21. Serum Concentration of Free Elranatamab

    Time frame: Predose, 6, 24, and 48 hours post dose on Cycle (C) 1 Day (D) 1; Predose and 24 hours post dose on C1D4; Predose and 6 hours post dose on C1D8; Predose on C1D15; C1D22; C2D1; C3D1; C4D1; C7D1; and C10D1

  22. Percentage of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Against Elranatamab

    A participant was ADA or NAb positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-fold dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).

    Time frame: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)

  23. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life of Cancer Participants Core Module (EORTC QLQ-C30) at Cycle 9 Day 1

    EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea and vomiting, and pain), 6 single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) and a global health status/QoL scale. Functional scales ranged from 0 (low functioning) to 100 (high functioning) where, higher score= higher levels of functioning. Symptom scales ranged from 0 (no symptoms) to 100 (worse symptoms) where, higher scores= worse symptoms/greater burden. Single item scores ranged from 0 (no problem) to 100 (severe problems) where, higher scores= more severe symptoms/problem. The global health status/QoL also ranged from 0 (low health status/QoL) to 100 (good health status/QoL). Higher scores on the global health status/QoL represent higher health status/quality of life.

    Time frame: Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1

  24. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma-Specific Module (EORTC QLQ-MY20) at Cycle 9 Day 1

    EORTC QLQ-MY20 is a myeloma-specific module developed by the EORTC group specifically to assess quality of life in participants with multiple myeloma. It contains 20 items which can be grouped into a disease symptom subscale (6 items), side effects of treatment subscale (10 items), body image (1 item) and future perspective subscale (3 items). The Disease Symptoms and Side Effects of Treatment subscale ranged from 0 (no symptoms/side effects) to 100 (worse symptoms/side effects) with higher scores indicating worse symptoms. The Future Perspective and Body Image subscale ranged from 0 (worst support/functioning) to 100 (best support/functioning) with higher scores indicating better support/functioning (Future Perspective and Body Image).

    Time frame: Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1

  25. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ CIPN20) at Cycle 9 Day 1

    EORTC QLQ CIPN20 is a module developed by the EORTC group to assess chemotherapy-induced peripheral neuropathy. It contains 20 items which can be grouped into a sensory subscale (9 items), motor subscale (8 items) and autonomic subscale (3 items). Sensory scale scores range from 0 (no sensory symptoms) to 100 (severe sensory symptoms), motor scale scores range from 0 (no motor impairment) to 100 (greater motor impairment), and autonomic scale scores range from 0 (minimal symptoms) to 100 (worse autonomic symptoms). Higher scores indicate worse neuropathy.

    Time frame: Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1

  26. Change From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Index Score and in EQ-5D Visual Analogue Score (EQ-VAS) at Cycle 9 Day 1

    EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and VAS. EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, UK look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS. higher scores indicated better health states.

    Time frame: Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1

08

Results

Posted Sep 19, 2024

Participant flow

Participants with relapsed/refractory multiple myeloma (RRMM), who were refractory to at least 1 proteasome inhibitor (PI), 1 immunomodulatory drug (IMiD), and 1 anti-cluster of differentiation38 monoclonal antibody (anti-CD38 mAB) were included.

Participant flow — Overall Study
MilestonePhase 2Phase 1b
Started318
Treated308
Completed00
Not completed318
Withdrew: Death156
Withdrew: Withdrawal by subject81
Withdrew: Other71
Withdrew: Enrolled but not treated10

Outcome measures

PrimaryPhase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)

Grade(G)4 neutropenia \>5 day; febrile neutropenia (absolute neutrophil count \[ANC\] \<1000/millimeter cube (mm\^3) with single temperature \>38.3 degree Celsius (deg C) or sustained temp\>=38 deg C for \>1 hour(H); G\>=3 neutropenia with infection; G4 thrombocytopenia (unless baseline count \>=25,000/mm\^3 and \<50,000/mm\^3, in which case G4 thrombocytopenia to be accompanied by \>=G2 bleeding); Platelet count \<10,000/mm\^3; G3 thrombocytopenia with \>=G2 bleeding; G\>=4 AE; G3 cytokine release syndrome(CRS) except CRS not maximally treated/improved to \<=G1 within 48H; G3 AE except AE attributed to CRS, G3 nausea,vomiting,diarrhea improved to G\<=2 within 72H after medical management, G3 fatigue \<1 week, G3 AE recovered to baseline/G1 within 5 day; confirmed drug-induced liver injury; G3-4 laboratory (lab) abnormality except G3-4 lab abnormality improved to G\<=2 within 72H after medical management \& without sequelae;G3 injection site reaction; G2/other clinically important AE may be considered DLT.

Time frame:
Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)
ParticipantsPhase 1b
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)1
PrimaryObjective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria

ORR: Percentage of participants with best overall response (BOR) of confirmed stringent complete response (sCR), CR, very good partial response (VGPR) or PR per IMWG criteria. sCR: CR and normal serum free light chain (sFLC) ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \& urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum \& urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein \& reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum \& urine M-protein were unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% \& \>=50% reduction in soft tissue plasmacytomas' size.

Time frame:
From date of first dose until confirmed disease progression (PD), death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria
Percentage of participantsPhase 1bPhase 2Phase 1b + Phase 2
Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria37.5 (8.5 to 75.5)53.3 (34.3 to 71.7)50.0 (33.4 to 66.6)
Statistical analysis
  • Phase 1b + Phase 2 · Exact binomial test · p = 0.0076
SecondaryDuration of Response (DOR) as Per IMWG Criteria by BICR

DOR: Time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell percentage irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion, \>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

Time frame:
From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
Reported as:
Median · Months
Duration of Response (DOR) as Per IMWG Criteria by BICR
MonthsPhase 1bPhase 2Phase 1b + Phase 2
Duration of Response (DOR) as Per IMWG Criteria by BICR8.7 (7.4 to NA)13.7 (2.8 to NA)8.7 (3.7 to NA)
SecondaryDOR as Per IMWG Criteria by Investigator Assessment

DOR: Time from first documentation of objective response subsequently confirmed, until first documentation of confirmed PD or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell percentage irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

Time frame:
From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
Reported as:
Median · Months
DOR as Per IMWG Criteria by Investigator Assessment
MonthsPhase 1bPhase 2Phase 1b + Phase 2
DOR as Per IMWG Criteria by Investigator Assessment8.7 (7.5 to NA)NA (3.7 to NA)18.5 (6.9 to NA)
SecondaryComplete Response Rate (CRR) as Per IMWG Criteria by BICR

CRR: Percentage of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/bone marrow aspiration (BMB/BMA) by immunohistochemistry (IH), immunofluorescence (IF), or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.

Time frame:
From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Number · Percentage of participants
Complete Response Rate (CRR) as Per IMWG Criteria by BICR
Percentage of participantsPhase 1bPhase 1b + Phase 2Phase 2
Complete Response Rate (CRR) as Per IMWG Criteria by BICR25.0 (3.2 to 65.1)21.1 (9.6 to 37.3)20.0 (7.7 to 38.6)
SecondaryCRR as Per IMWG Criteria by Investigator Assessment

CRR: Percentage of participants with BOR of confirmed sCR/CR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio.

Time frame:
From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Number · Percentage of participants
CRR as Per IMWG Criteria by Investigator Assessment
Percentage of participantsPhase 1bPhase 1b + Phase 2Phase 2
CRR as Per IMWG Criteria by Investigator Assessment25.0 (3.2 to 65.1)18.4 (7.7 to 34.3)16.7 (5.6 to 34.7)
SecondaryORR as Per IMWG Criteria by Investigator Assessment

ORR: Percentage of participants with best overall response of confirmed sCR, CR, VGPR or PR per IMWG criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein and urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein were unmeasurable, VGPR and PR: \>=90% and \>=50% decrease in difference respectively between involved and uninvolved sFLC levels and if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.

Time frame:
From date of first dose until confirmed PD, death due to any cause, or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Number · Percentage of participants
ORR as Per IMWG Criteria by Investigator Assessment
Percentage of participantsPhase 1bPhase 1b + Phase 2Phase 2
ORR as Per IMWG Criteria by Investigator Assessment37.5 (8.5 to 75.5)44.7 (28.6 to 61.7)46.7 (28.3 to 65.7)
SecondaryDuration of Complete Response (DOCR) as Per IMWG Criteria by BICR

DOCR: Time from first documentation of sCR/CR subsequently confirmed, until first documentation of confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

Time frame:
From the first documentation of sCR/CR, until confirmed PD, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Median · Months
Duration of Complete Response (DOCR) as Per IMWG Criteria by BICR
MonthsPhase 1bPhase 1b + Phase 2Phase 2
Duration of Complete Response (DOCR) as Per IMWG Criteria by BICRNA (NA to NA)NA (1.6 to NA)NA (1.6 to NA)
SecondaryDOCR as Per IMWG Criteria by Investigator Assessment

DOCR: Time from first documentation of sCR/CR subsequently confirmed, until first documentation of confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

Time frame:
From the first documentation of sCR/CR, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Median · Months
DOCR as Per IMWG Criteria by Investigator Assessment
MonthsPhase 1bPhase 1b + Phase 2Phase 2
DOCR as Per IMWG Criteria by Investigator AssessmentNA (NA to NA)NA (1.7 to NA)NA (1.7 to NA)
SecondaryProgression Free Survival (PFS) as Per IMWG Criteria by BICR

PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

Time frame:
From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
Reported as:
Median · Months
Progression Free Survival (PFS) as Per IMWG Criteria by BICR
MonthsPhase 1bPhase 1b + Phase 2Phase 2
Progression Free Survival (PFS) as Per IMWG Criteria by BICR1.8 (0.6 to 9.9)5.7 (2.2 to 8.0)5.7 (2.3 to 8.0)
SecondaryPFS as Per IMWG Criteria by Investigator Assessment

PFS was defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5g/dL\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200mg/24h\]; participants without measurable serum and urine M-protein levels, difference between involved and uninvolved sFLC levels \[absolute increase \>10mg/dL\]; in participants without measurable serum, urine M-protein levels and involved sFLC levels: bone marrow plasma-cell % irrespective of baseline status \[absolute increase \>=10%\]; appearance of new lesion,\>=50% increase from nadir in SPD of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1cm in short axis; \>=50% increase in circulating plasma cells \[\>=200cells/μL\] if this is the only measure of disease.

Time frame:
From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
Reported as:
Median · Months
PFS as Per IMWG Criteria by Investigator Assessment
MonthsPhase 1bPhase 2Phase 1b + Phase 2
PFS as Per IMWG Criteria by Investigator Assessment1.8 (0.6 to 9.9)5.7 (2.3 to NA)5.7 (2.2 to 9.9)
SecondaryOverall Survival (OS)

OS was defined as time from date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive

Time frame:
From the date of first dose until death due to any cause or censoring date (up to 38.8 months of follow-up)
Reported as:
Median · Months
Overall Survival (OS)
MonthsPhase 1bPhase 1b + Phase 2Phase 2
Overall Survival (OS)4.0 (1.2 to 14.4)9.0 (4.0 to 14.9)9.0 (5.5 to 16.7)
SecondaryTime-to-Response (TTR) as Per IMWG Criteria by BICR

TTR, for participants with objective response (OR) per IMWG criteria: time from date of first dose to first documentation of OR that was subsequently confirmed. OR: BOR of confirmed sCR, CR, VGPR or PR. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measured sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/ \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.

Time frame:
From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)
Reported as:
Median · Months
Time-to-Response (TTR) as Per IMWG Criteria by BICR
MonthsPhase 1bPhase 1b + Phase 2Phase 2
Time-to-Response (TTR) as Per IMWG Criteria by BICR2.04 (1.15 to 4.73)1.51 (0.95 to 5.52)1.45 (0.95 to 5.52)
SecondaryTTR as Per IMWG Criteria by Investigator Assessment

TTR, for participants with OR per IMWG criteria: time from date of first dose to first documentation of OR that was subsequently confirmed. OR: BOR of confirmed sCR, CR, VGPR or PR. sCR: CR and normal sFLC ratio and absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma \& \<5% plasma cells in BMA, if disease measured sFLC only, preceding criteria plus normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis/ \>=90% reduction in serum M-protein \& urine M-protein level \<100mg/24h. PR: \>=50% reduction in serum M-protein and reduction in 24h urinary M-protein by \>=90% or \<200 mg/24h. If serum and urine M-protein unmeasurable, VGPR \& PR: \>=90% \& \>=50% decrease in difference respectively between involved \& uninvolved sFLC levels \& if present at baseline, \>=90% and \>=50% reduction in soft tissue plasmacytomas' size.

Time frame:
From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Median · Months
TTR as Per IMWG Criteria by Investigator Assessment
MonthsPhase 1bPhase 1b + Phase 2Phase 2
TTR as Per IMWG Criteria by Investigator Assessment2.04 (1.15 to 2.79)1.22 (0.95 to 4.01)1.2 (0.95 to 4.01)
SecondaryMinimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria by BICR

MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/ bone marrow aspirate (BMB/BMA) by immunohistochemistry, immunofluorescence, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. MRD negativity rate at threshold of 10\^-5 is reported in this outcome measure.

Time frame:
From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Number · Percentage of participants
Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria by BICR
Percentage of participantsPhase 1bPhase 1b + Phase 2Phase 2
Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria by BICR100.0 (15.81 to 100.0)85.7 (42.13 to 99.64)80.0 (28.36 to 99.49)
SecondaryMRD Negativity Rate Per IMWG Sequencing Criteria by Investigator Assessment

MRD negativity rate was the percentage of participants with CR/sCR and with negative MRD per IMWG sequencing criteria. sCR: CR and normal sFLC ratio and absence of clonal cells in bone marrow biopsy/ bone marrow aspirate (BMB/BMA) by immunohistochemistry, immunofluorescence, or flow cytometry. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytoma and \<5% plasma cells in BMA, if disease measurable by sFLC only, preceding criteria plus normal sFLC ratio. MRD negativity rate at threshold of 10\^-5 is reported in this outcome measure.

Time frame:
From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Number · Percentage of participants
MRD Negativity Rate Per IMWG Sequencing Criteria by Investigator Assessment
Percentage of participantsPhase 1bPhase 1b + Phase 2Phase 2
MRD Negativity Rate Per IMWG Sequencing Criteria by Investigator Assessment100.0 (15.81 to 100.0)85.7 (42.13 to 99.64)80.0 (28.36 to 99.49)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE), Serious TEAEs, Treatment Related TEAEs, Serious Treatment Related TEAEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

AE: any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to study intervention. Serious adverse event (SAE): any untoward medical occurrence that, at any dose resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. An AE was considered treatment-emergent if it occurred from the first dose of the study intervention until 90 days after the last dose or the day before starting a new anticancer therapy, whichever occurred first. AEs included both SAEs and all other AEs. AEs were graded using CTCAE version 5.0, where Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening; Grade 5: death. Relatedness to study intervention was judged by investigator.

Time frame:
From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE), Serious TEAEs, Treatment Related TEAEs, Serious Treatment Related TEAEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
ParticipantsPhase 1bPhase 1b + Phase 2Phase 2
Participants With TEAEs83830
Participants With Serious TEAEs62822
Participants with Maximum Grade 3 or 4 TEAEs42420
Participants with Maximum Grade 5 TEAEs4139
Participants With Treatment Related TEAEs73730
Participants With Treatment Related Serious TEAEs42117
Participants with Maximum Grade 3 or 4 Treatment Related TEAEs52722
Participants with Maximum Grade 5 Treatment Related TEAEs154
SecondaryNumber of Participants With Cytokine Release Syndrome (CRS) of Any Grade According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria

ASTCT CRS Grading: Grade 1: temperature \>=38 degree Celsius (deg C) without hypotension or hypoxia; Grade 2: temperature \>=38 deg C with hypotension not requiring vasopressors, and/or hypoxia requiring low-flow nasal cannula, facemask or blow-by; Grade 3: temperature \>=38 deg C with hypotension requiring a vasopressor with or without vasopressin and/or hypoxia requiring high-flow nasal cannula, high-flow facemask, nonrebreather mask, or Venturi mask; Grade 4: temperature \>=38 deg C with hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive pressure (e.g., continuous positive airway pressure \[CPAP\], bilevel positive airway pressure \[BiPAP\], intubation and mechanical ventilation); Grade 5: death. Number of participants with CRS of any grade is reported in this outcome measure.

Time frame:
From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Count of participants · Participants
Number of Participants With Cytokine Release Syndrome (CRS) of Any Grade According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria
ParticipantsPhase 1bPhase 1b + Phase 2Phase 2
Number of Participants With Cytokine Release Syndrome (CRS) of Any Grade According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria31916
SecondaryNumber of Participants With Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) of Any Grade According to ASTCT Criteria

ICANS Grade 1: immune effector cell encephalopathy (ICE) score 7-9, participant (P) awakens spontaneously; Grade 2: ICE score 3-6, P awakens to voice; Grade 3: ICE score 0-2, P awakens only to tactile stimulus, any clinical seizure focal or generalized that resolved rapidly/nonconvulsive seizures on electroencephalography that resolved with intervention or focal/local edema on neuroimaging; Grade 4: ICE score 0 (P unarousable and unable to perform ICE), P unarousable/required vigorous/repetitive tactile stimuli to arouse, life-threatening prolonged seizure (\>5 minutes), repetitive clinical/electrical seizures without return to baseline in between, deep focal motor weakness, diffuse cerebral edema on neuroimaging; decerebrate/decorticate posturing; cranial nerve VI palsy; papilledema, Cushing's triad; Grade 5: death. ICE: measures alterations in speech, orientation, handwriting, attention and receptive aphasia. Number of participants with ICANS of any grade reported.

Time frame:
From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Count of participants · Participants
Number of Participants With Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) of Any Grade According to ASTCT Criteria
ParticipantsPhase 1bPhase 1b + Phase 2Phase 2
Number of Participants With Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) of Any Grade According to ASTCT Criteria000
SecondaryMaximum Serum Concentration (Cmax) of Free Elranatamab
Time frame:
Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
Reported as:
Geometric mean · Microgram per milliliter
Maximum Serum Concentration (Cmax) of Free Elranatamab
Microgram per milliliterPhase 2Phase 1bPhase 1b + Phase 2
Maximum Serum Concentration (Cmax) of Free Elranatamab0.8039 ± 240.8762 ± 660.842 ± 48
SecondaryTime To Maximum Serum Concentration (Tmax) of Free Elranatamab
Time frame:
Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
Reported as:
Median · Days
Time To Maximum Serum Concentration (Tmax) of Free Elranatamab
DaysPhase 2Phase 1bPhase 1b + Phase 2
Time To Maximum Serum Concentration (Tmax) of Free Elranatamab8.0 (6.94 to 11.0)7.0 (3.93 to 9.97)7.0 (3.93 to 11.0)
SecondaryArea Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of Free Elranatamab
Time frame:
Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
Reported as:
Geometric mean · Microgram*day per milliliter
Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of Free Elranatamab
Microgram*day per milliliterPhase 2Phase 1bPhase 1b + Phase 2
Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of Free Elranatamab3.864 ± 373.482 ± 743.653 ± 56
SecondarySerum Concentration of Free Elranatamab
Time frame:
Predose, 6, 24, and 48 hours post dose on Cycle (C) 1 Day (D) 1; Predose and 24 hours post dose on C1D4; Predose and 6 hours post dose on C1D8; Predose on C1D15; C1D22; C2D1; C3D1; C4D1; C7D1; and C10D1
Reported as:
Geometric mean · Nanogram per milliliter
Serum Concentration of Free Elranatamab
Nanogram per milliliterPhase 2Phase 1bPhase 1b + Phase 2
Predose on C1D1NA ± NANA ± NANA ± NA
6 hours post dose on C1D180.02 ± 3979.54 ± 8179.85 ± 52
24 hours post dose on C1D1131.3 ± 41144.1 ± 70133.9 ± 47
48 hours post dose on C1D1285.3 ± 33230.1 ± 56252.3 ± 47
Predose on C1D4288.2 ± 40272.1 ± 43285.1 ± 40
24 hours post dose on C1D4445.3 ± 42628.7 ± 94475.4 ± 54
Predose on C1D8757.0 ± 53697.3 ± 72743.7 ± 57
6 hours post dose on C1D81148 ± 521026 ± 811121 ± 58
Predose on C1D153097 ± 682264 ± 1042914 ± 75
Predose on C1D224511 ± 1043569 ± 1284311 ± 107
Predose on C2D17960 ± 887423 ± 487891 ± 82
Predose on C3D111470 ± 111NA ± NA11030 ± 102
Predose on C4D110980 ± 348NA ± NA11580 ± 282
Predose on C7D118410 ± 676830023930 ± 93
Predose on C10D113430 ± 293420015690 ± 49
SecondaryPercentage of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Against Elranatamab

A participant was ADA or NAb positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-fold dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).

Time frame:
From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
Reported as:
Number · Percentage of participants
Percentage of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Against Elranatamab
Percentage of participantsPhase 2Phase 1bPhase 1b + Phase 2
ADA4.00.03.2
NAb4.00.03.2
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life of Cancer Participants Core Module (EORTC QLQ-C30) at Cycle 9 Day 1

EORTC QLQ-C30 contains 30 items and is composed of both multi-item scales and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea and vomiting, and pain), 6 single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) and a global health status/QoL scale. Functional scales ranged from 0 (low functioning) to 100 (high functioning) where, higher score= higher levels of functioning. Symptom scales ranged from 0 (no symptoms) to 100 (worse symptoms) where, higher scores= worse symptoms/greater burden. Single item scores ranged from 0 (no problem) to 100 (severe problems) where, higher scores= more severe symptoms/problem. The global health status/QoL also ranged from 0 (low health status/QoL) to 100 (good health status/QoL). Higher scores on the global health status/QoL represent higher health status/quality of life.

Time frame:
Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
Reported as:
Mean · Units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life of Cancer Participants Core Module (EORTC QLQ-C30) at Cycle 9 Day 1
Units on a scalePhase 2Phase 1bPhase 1b + Phase 2
Global QOL1.19 ± 13.9685.56 ± 4.8112.5 ± 11.818
Physical Functioning-11.43 ± 24.85920.0 ± 29.059-2.0 ± 28.812
Role Functioning-14.29 ± 50.39511.11 ± 19.245-6.67 ± 43.885
Emotional Functioning-5.95 ± 14.203-2.78 ± 4.811-5.0 ± 11.915
Cognitive Functioning-7.14 ± 21.2070.0 ± 0.0-5.0 ± 17.656
Social Functioning-14.29 ± 33.9235.56 ± 19.245-8.33 ± 30.682
Fatigue12.7 ± 31.706-14.81 ± 12.834.44 ± 29.722
Nausea and Vomiting0.0 ± 0.00.0 ± 0.00.0 ± 0.0
Pain2.38 ± 37.796-27.78 ± 25.459-6.67 ± 36.175
Dyspnoea0.0 ± 0.0-11.11 ± 19.245-3.33 ± 10.541
Insomnia14.29 ± 17.817-22.22 ± 19.2453.33 ± 24.595
Appetite Loss0.0 ± 19.24522.22 ± 19.2456.67 ± 21.082
Constipation14.29 ± 17.8170.0 ± 0.010.0 ± 16.102
Diarrhea-4.76 ± 12.599-11.11 ± 19.245-6.67 ± 14.055
Financial Difficulties4.76 ± 23.0020.0 ± 33.3333.33 ± 24.595
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma-Specific Module (EORTC QLQ-MY20) at Cycle 9 Day 1

EORTC QLQ-MY20 is a myeloma-specific module developed by the EORTC group specifically to assess quality of life in participants with multiple myeloma. It contains 20 items which can be grouped into a disease symptom subscale (6 items), side effects of treatment subscale (10 items), body image (1 item) and future perspective subscale (3 items). The Disease Symptoms and Side Effects of Treatment subscale ranged from 0 (no symptoms/side effects) to 100 (worse symptoms/side effects) with higher scores indicating worse symptoms. The Future Perspective and Body Image subscale ranged from 0 (worst support/functioning) to 100 (best support/functioning) with higher scores indicating better support/functioning (Future Perspective and Body Image).

Time frame:
Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
Reported as:
Mean · Units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma-Specific Module (EORTC QLQ-MY20) at Cycle 9 Day 1
Units on a scalePhase 2Phase 1bPhase 1b + Phase 2
Body Image-19.05 ± 37.79611.11 ± 19.245-10.0 ± 35.312
Future Perspective-11.11 ± 15.7130.0 ± 22.222-7.78 ± 17.411
Disease Symptoms-1.59 ± 18.346-5.56 ± 11.111-2.78 ± 15.984
Side Effects of Treatment2.28 ± 9.683-7.78 ± 13.461-0.74 ± 11.241
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ CIPN20) at Cycle 9 Day 1

EORTC QLQ CIPN20 is a module developed by the EORTC group to assess chemotherapy-induced peripheral neuropathy. It contains 20 items which can be grouped into a sensory subscale (9 items), motor subscale (8 items) and autonomic subscale (3 items). Sensory scale scores range from 0 (no sensory symptoms) to 100 (severe sensory symptoms), motor scale scores range from 0 (no motor impairment) to 100 (greater motor impairment), and autonomic scale scores range from 0 (minimal symptoms) to 100 (worse autonomic symptoms). Higher scores indicate worse neuropathy.

Time frame:
Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
Reported as:
Mean · Units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ CIPN20) at Cycle 9 Day 1
Units on a scalePhase 2Phase 1bPhase 1b + Phase 2
Sensory Subscale3.17 ± 10.1270.0 ± 0.02.22 ± 8.41
Motor Subscale10.71 ± 25.057-7.54 ± 7.1765.24 ± 22.533
Autonomic Subscale3.97 ± 6.964-16.67 ± 5.556-2.22 ± 11.771
SecondaryChange From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Index Score and in EQ-5D Visual Analogue Score (EQ-VAS) at Cycle 9 Day 1

EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and VAS. EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, UK look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS. higher scores indicated better health states.

Time frame:
Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Index Score and in EQ-5D Visual Analogue Score (EQ-VAS) at Cycle 9 Day 1
Units on a scalePhase 2Phase 1bPhase 1b + Phase 2
EQ-5D Index Score-0.06 ± 0.2520.13 ± 0.207-0.01 ± 0.246
EQ-VAS-5 ± 7.076 ± 5.29-1.7 ± 8.23

Adverse events

Collected over AEs: From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 217/30 (56.7%)22/30 (73.3%)30/30 (100%)
Phase 1b6/8 (75%)6/8 (75%)8/8 (100%)
Phase 1b + Phase 223/38 (60.5%)28/38 (73.7%)38/38 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventPhase 2Phase 1bPhase 1b + Phase 2
PneumoniaInfections and infestations12/303/815/38
AnaemiaBlood and lymphatic system disorders0/301/81/38
CoagulopathyBlood and lymphatic system disorders0/301/81/38
NeutropeniaBlood and lymphatic system disorders0/301/81/38
ThrombocytopeniaBlood and lymphatic system disorders0/301/81/38
Gastrointestinal haemorrhageGastrointestinal disorders0/301/81/38
FatigueGeneral disorders0/301/81/38
Cytokine release syndromeImmune system disorders1/301/82/38
COVID-19Infections and infestations2/301/83/38
GastroenteritisInfections and infestations0/301/81/38
Most frequent other events
Showing 10 of 105
Most frequent other events
EventPhase 2Phase 1bPhase 1b + Phase 2
ThrombocytopeniaBlood and lymphatic system disorders20/308/828/38
LeukopeniaBlood and lymphatic system disorders21/307/828/38
NeutropeniaBlood and lymphatic system disorders22/307/829/38
AnaemiaBlood and lymphatic system disorders20/306/826/38
COVID-19Infections and infestations20/303/823/38
SARS-CoV-2 test positiveInvestigations20/303/823/38
PneumoniaInfections and infestations12/305/817/38
HypokalaemiaMetabolism and nutrition disorders17/305/822/38
HyponatraemiaMetabolism and nutrition disorders8/305/813/38
LymphopeniaBlood and lymphatic system disorders16/304/820/38

Baseline characteristics

Safety analysis set included all participants enrolled to study who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Phase 1bPhase 2Total
Mean54.8 ± 12.1962.3 ± 7.5360.7 ± 9.07
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1bPhase 2Total
Female41216
Male41822
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1bPhase 2Total
Hispanic or Latino000
Not Hispanic or Latino83038
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1bPhase 2Total
American Indian or Alaska Native000
Asian83038
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
09

Study locations

15 sites
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510555, China
  • Shenzhen Second People's Hosptial
    Shenzhen, Guangdong 518035, China
  • Harbin First Hospital
    Harbin, Heilongjiang 150010, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Beijing Gaobo Boren Hospital
    Beijing, 100070, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Hematology Hospital, Chinese Academy of Medical Sciences
    Tianjin, 300020, China
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Aug 2023, 19 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 19 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Feb 8, 2022
StartActual
Dec 21, 2021
Primary completionActual
Aug 6, 2023
CompletionActual
Sep 11, 2025
Results first posted
Sep 19, 2024
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Sep 29, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameObjective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) CriteriaFrom date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months) → From date of first dose until confirmed disease progression (PD), death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)
  • DescriptionObjective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria: how it is measured was reworded
Sep 29, 2026
Documents
Sep 29, 2026
Secondary outcomes
13 edited, 12 time frame changed, 1 added, 4 description edited, 4 more
What changed in the outcomes
  • EditedDuration of Response (DOR) as Per IMWG Criteria by Investigator AssessmentTime frame: From first documentation of objective response subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
  • EditedComplete Response Rate (CRR) as Per IMWG Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 37 months) → From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
  • EditedObjective Response Rate (ORR) as Per IMWG Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 37 months) → From date of first dose until confirmed PD, death due to any cause, or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
  • EditedDuration of Complete Response (DOCR) as Per IMWG Criteria by Investigator AssessmentTime frame: From the first documentation of sCR/CR, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first (up to approximately 37 months) → From the first documentation of sCR/CR, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)
  • EditedProgression Free Survival (PFS) as Per IMWG Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
  • EditedTime-to-Response (TTR) as Per IMWG Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurs first (up to approximately 37 months) → From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
  • EditedMinimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria by BICRTime frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 37 months) → From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
  • EditedNumber of Participants With Cytokine Release Syndrome (CRS) Gradedof Any Grade According to American Society for Transplantation and Cellular Therapy (ASTCT) CriteriaTime frame: From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 37 months) → From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
  • EditedNumber of Participants With Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Gradedof Any Grade According to ASTCT CriteriaTime frame: From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 37 months) → From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
  • EditedChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life of Cancer Participants Core Module (EORTC QLQ-C30) at Cycle 9 Day 1Time frame: Baseline and up to 37 months → Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
  • EditedChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma-Specific Module (EORTC QLQ-MY20) at Cycle 9 Day 1Time frame: Baseline and up to 37 months → Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
  • EditedChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ CIPN20) at Cycle 9 Day 1Time frame: Baseline and up to 37 months → Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
  • EditedChange From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Index Score and in EQ-5D Visual Analogue Score (VAS) (EQ-VAS) at Cycle 9 Day 1Time frame: Baseline and up to 37 months → Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
  • AddedMRD Negativity Rate Per IMWG Sequencing Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
  • Time frameDuration of Response (DOR) as Per IMWG Criteria by BICRFrom first documentation of objective response subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
  • Time frameComplete Response Rate (CRR) as Per IMWG Criteria by BICRFrom date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 37 months) → From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
  • Time frameDuration of Complete Response (DOCR) as Per IMWG Criteria by BICRFrom first documentation of sCR/CR subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From the first documentation of sCR/CR, until confirmed PD, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)
  • Time frameProgression Free Survival (PFS) as Per IMWG Criteria by BICRFrom date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
  • Time frameOverall Survival (OS)From the date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive (up to approximately 37 months) → From the date of first dose until death due to any cause or censoring date (up to 38.8 months of follow-up)
  • Time frameTime-to-Response (TTR) as Per IMWG Criteria by BICRFrom date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurs first (approximately up to 16 months) → From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)
  • Time frameNumber of Participants With Treatment Emergent Adverse Events (TEAE), Serious TEAEs, Treatment Related TEAEs, Serious Treatment Related TEAEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 37 months) → From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
  • Time frameMaximum Serum Concentration (Cmax) of Free ElranatamabCycle 1: Pre-dose, 6 hours post-dose on Day 1, 24, 48 hours post-dose, Day 4: pre-dose, 24 hour post-dose, Day 8 pre-dose, 6 hours post-dose, Day 15,22: pre-dose, Cycles 2, 3 ,4,7: pre-dose (1 cycle =28 days) → Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
  • Time frameTime To Maximum Serum Concentration (Tmax) of Free ElranatamabCycle 1: Pre-dose, 6 hours post-dose on Day 1, 24, 48 hours post-dose, Day 4: pre-dose, 24 hour post-dose, Day 8 pre-dose, 6 hours post-dose, Day 15,22: pre-dose, Cycles 2, 3 ,4,7: pre-dose (1 cycle =28 days) → Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
  • Time frameArea Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of Free ElranatamabCycle 1: Pre-dose, 6 hours post-dose on Day 1, 24, 48 hours post-dose, Day 4: pre-dose, 24 hour post-dose, Day 8 pre-dose, 6 hours post-dose, Day 15,22: pre-dose, Cycles 2, 3 ,4,7: pre-dose (1 cycle =28 days) → Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
  • Time frameSerum Concentration of Free ElranatamabUp to 37 months → Predose, 6, 24, and 48 hours post dose on Cycle (C) 1 Day (D) 1; Predose and 24 hours post dose on C1D4; Predose and 6 hours post dose on C1D8; Predose on C1D15; C1D22; C2D1; C3D1; C4D1; C7D1; and C10D1
  • Time framePercentage of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Against ElranatamabFrom the date of first dose up to 37 months → From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
  • DescriptionComplete Response Rate (CRR) as Per IMWG Criteria by BICR: how it is measured was reworded
  • DescriptionDuration of Complete Response (DOCR) as Per IMWG Criteria by BICR: how it is measured was reworded
  • DescriptionDuration of Response (DOR) as Per IMWG Criteria by BICR: how it is measured was reworded
  • DescriptionNumber of Participants With Treatment Emergent Adverse Events (TEAE), Serious TEAEs, Treatment Related TEAEs, Serious Treatment Related TEAEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0: how it is measured was reworded
  • …and 4 more, on the record history on ClinicalTrials.gov ↗
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Posted results revised
    Documents Study protocol ↗ updated
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameObjective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) CriteriaFrom date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months) → From date of first dose until confirmed disease progression (PD), death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)
    • DescriptionObjective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria: how it is measured was reworded
    Secondary outcomes 13 edited, 12 time frame changed, 1 added, 4 description edited, 4 more
    What changed in the outcomes
    • EditedDuration of Response (DOR) as Per IMWG Criteria by Investigator AssessmentTime frame: From first documentation of objective response subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
    • EditedComplete Response Rate (CRR) as Per IMWG Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 37 months) → From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
    • EditedObjective Response Rate (ORR) as Per IMWG Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 37 months) → From date of first dose until confirmed PD, death due to any cause, or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
    • EditedDuration of Complete Response (DOCR) as Per IMWG Criteria by Investigator AssessmentTime frame: From the first documentation of sCR/CR, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first (up to approximately 37 months) → From the first documentation of sCR/CR, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)
    • EditedProgression Free Survival (PFS) as Per IMWG Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
    • EditedTime-to-Response (TTR) as Per IMWG Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurs first (up to approximately 37 months) → From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
    • EditedMinimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria by BICRTime frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 37 months) → From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
    • EditedNumber of Participants With Cytokine Release Syndrome (CRS) Gradedof Any Grade According to American Society for Transplantation and Cellular Therapy (ASTCT) CriteriaTime frame: From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 37 months) → From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
    • EditedNumber of Participants With Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Gradedof Any Grade According to ASTCT CriteriaTime frame: From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 37 months) → From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
    • EditedChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life of Cancer Participants Core Module (EORTC QLQ-C30) at Cycle 9 Day 1Time frame: Baseline and up to 37 months → Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
    • EditedChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Myeloma-Specific Module (EORTC QLQ-MY20) at Cycle 9 Day 1Time frame: Baseline and up to 37 months → Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
    • EditedChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ CIPN20) at Cycle 9 Day 1Time frame: Baseline and up to 37 months → Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
    • EditedChange From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Index Score and in EQ-5D Visual Analogue Score (VAS) (EQ-VAS) at Cycle 9 Day 1Time frame: Baseline and up to 37 months → Baseline (prior to the date of the first dose of study intervention), and Cycle 9 Day 1
    • AddedMRD Negativity Rate Per IMWG Sequencing Criteria by Investigator AssessmentTime frame: From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
    • Time frameDuration of Response (DOR) as Per IMWG Criteria by BICRFrom first documentation of objective response subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From first documentation of objective response until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
    • Time frameComplete Response Rate (CRR) as Per IMWG Criteria by BICRFrom date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 37 months) → From date of first dose until confirmed PD, death or start of new anticancer therapy, whichever occurred first (up to 38.8 months of follow-up)
    • Time frameDuration of Complete Response (DOCR) as Per IMWG Criteria by BICRFrom first documentation of sCR/CR subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From the first documentation of sCR/CR, until confirmed PD, or death due to any cause, whichever occurred first (up to 38.8 months of follow-up)
    • Time frameProgression Free Survival (PFS) as Per IMWG Criteria by BICRFrom date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 37 months) → From date of first dose until confirmed PD per IMWG criteria or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring date (up to 38.8 months of follow-up)
    • Time frameOverall Survival (OS)From the date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive (up to approximately 37 months) → From the date of first dose until death due to any cause or censoring date (up to 38.8 months of follow-up)
    • Time frameTime-to-Response (TTR) as Per IMWG Criteria by BICRFrom date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurs first (approximately up to 16 months) → From date of first dose until confirmed PD per IMWG criteria, death, start of new anticancer therapy, whichever occurred first (approximately up to 16 months)
    • Time frameNumber of Participants With Treatment Emergent Adverse Events (TEAE), Serious TEAEs, Treatment Related TEAEs, Serious Treatment Related TEAEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 37 months) → From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
    • Time frameMaximum Serum Concentration (Cmax) of Free ElranatamabCycle 1: Pre-dose, 6 hours post-dose on Day 1, 24, 48 hours post-dose, Day 4: pre-dose, 24 hour post-dose, Day 8 pre-dose, 6 hours post-dose, Day 15,22: pre-dose, Cycles 2, 3 ,4,7: pre-dose (1 cycle =28 days) → Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
    • Time frameTime To Maximum Serum Concentration (Tmax) of Free ElranatamabCycle 1: Pre-dose, 6 hours post-dose on Day 1, 24, 48 hours post-dose, Day 4: pre-dose, 24 hour post-dose, Day 8 pre-dose, 6 hours post-dose, Day 15,22: pre-dose, Cycles 2, 3 ,4,7: pre-dose (1 cycle =28 days) → Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
    • Time frameArea Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of Free ElranatamabCycle 1: Pre-dose, 6 hours post-dose on Day 1, 24, 48 hours post-dose, Day 4: pre-dose, 24 hour post-dose, Day 8 pre-dose, 6 hours post-dose, Day 15,22: pre-dose, Cycles 2, 3 ,4,7: pre-dose (1 cycle =28 days) → Cycle 1: Pre-dose on Day 1, 4, 8, 6, 24, 48, 120, and 198 hours post-dose; Day 15, 22: pre-dose; Cycles 2, 3 ,4, 7: pre-dose (1 cycle =28 days)
    • Time frameSerum Concentration of Free ElranatamabUp to 37 months → Predose, 6, 24, and 48 hours post dose on Cycle (C) 1 Day (D) 1; Predose and 24 hours post dose on C1D4; Predose and 6 hours post dose on C1D8; Predose on C1D15; C1D22; C2D1; C3D1; C4D1; C7D1; and C10D1
    • Time framePercentage of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Against ElranatamabFrom the date of first dose up to 37 months → From the date of first dose of study intervention up to 90 days after last dose of study intervention or start of new anticancer therapy whichever occurred first (up to 38.8 months of follow-up)
    • DescriptionComplete Response Rate (CRR) as Per IMWG Criteria by BICR: how it is measured was reworded
    • DescriptionDuration of Complete Response (DOCR) as Per IMWG Criteria by BICR: how it is measured was reworded
    • DescriptionDuration of Response (DOR) as Per IMWG Criteria by BICR: how it is measured was reworded
    • DescriptionNumber of Participants With Treatment Emergent Adverse Events (TEAE), Serious TEAEs, Treatment Related TEAEs, Serious Treatment Related TEAEs as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0: how it is measured was reworded
    • …and 4 more, on the record history on ClinicalTrials.gov ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05228470
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 8, 2022
Start date
Dec 21, 2021
Primary completion
Aug 6, 2023
Completion
Sep 11, 2025
Results posted
Sep 19, 2024
Last update
Sep 29, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elranatamab

Start the discussion